Platinum Compounds in the Treatment of Advanced Breast Cancer

This publication has 116 references indexed in Scilit:

• Pilot study of continuous low-dose 5-fluorouracil and cisplatin (FP regimen) for the treatment of metastatic breast cancer
  International Journal of Clinical Oncology, 2000
• A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma
  Cancer, 2000
• Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
  Biochemical Pharmacology, 1996
• Taxol and Cisplatin Inhibit Proliferation of T47D Human Breast Cancer Cells
  Biochemical and Biophysical Research Communications, 1994
• First-line combination chemotherapy with mitoxantrone, methotrexate, vincristine and carboplatin (MIMOC) in advanced breast cancer
  European Journal Of Cancer, 1993
• Therapy off patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatin
  Anti-Cancer Drugs, 1992
• Negative phase II study with carboplatin and 5-fluorouracil in advanced breast cancer
  European Journal Of Cancer, 1992
• Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian oncology group for clinical research (G.O.I.R.C.)
  European Journal of Cancer and Clinical Oncology, 1986
• Cisplatin plus vindesine in advanced breast cancer: a phase II trial of the EORTC breast cancer coooperative group
  European Journal of Cancer and Clinical Oncology, 1985
• Preliminary clinical experience withcis-diamminedichloroplatinum (II) (NSC 119875, CACP)
  Cancer, 1972